The Liver Meeting 2022 | MIMS Malaysia

Bepirovirsen shows promise in controlling chronic HBV infection

Roshini Claire Anthony, 20221219150001

Weekly bepirovirsen treatment may help reduce HBsAg* and hepatitis B virus (HBV) DNA levels in patients with chronic HBV infection, the phase IIb B-Clear study showed.

ALXN1840 generates rapid, sustained copper mobilization in Wilson disease

Audrey Abella, 20221215100000

In individuals with Wilson disease (WD), a rare disease of copper metabolism, ALXN1840 led to significantly greater copper mobilization compared with standard of care (SoC), findings from a rater-blinded phase III study have shown.

Maralixibat improves pruritus across all PFIC types

Elaine Soliven, 20221214000000

Treatment with maralixibat significantly reduced the severity of pruritus in children with progressive familial intrahepatic cholestasis (PFIC) in the MARCH-PFIC* study presented at The Liver Meeting 2022.

Odevixibat improves pruritus, reduces bile acids in children with ALGS

Elaine Soliven, 20221213000000

Treatment with odevixibat, a potent, selective IBAT* inhibitor, significantly improved pruritus and reduced serum bile acid levels in children with Alagille syndrome (ALGS), according to the ASSERT** trial presented at The Liver Meeting 2022.

Resmetirom safe, effective in improving NASH fibrosis markers

Audrey Abella, 20221212100000

Treatment with the selective THR-β* agonist resmetirom for 52 weeks was well-tolerated and effective in reducing markers of NASH** fibrosis in a well-compensated Child-Pugh (CP)-A NASH population, a phase III trial has shown.

Midodrine a novel option for PICD prevention in ACLF

Elvira Manzano, 20221206000000

Oral midodrine may be a good alternative to intravenous albumin for preventing paracentesis-induced circulatory dysfunction (PICD) in patients with acute-on-chronic liver failure (ACLF) undergoing modest-volume paracentesis for ascites, suggests a new study.